# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a re...
ALNY: 14% | Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Pha...
Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTU...
Piper Sandler analyst Yasmeen Rahimi maintains Altimmune (NASDAQ:ALT) with a Overweight and maintains $25 price target.
Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflam...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.